ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201247
CHEMBL1201247
Compound Name GOSERELIN
ChEMBL Synonyms GOSERELIN ACETATE | ZOLADEX LA | ICI 118,630 | NOVGOS | ZOLADEX | GOSERELIN
Max Phase 4 (Approved)
Trade Names NOVGOS | ZOLADEX | ZOLADEX LA
Molecular Formula C59H84N18O14

Additional synonyms for CHEMBL1201247 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1 ...
Download SMILES
Standard InChI InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-5 ...
Download InChI
Standard InChI Key BLCLNMBMMGCOAS-URPVMXJPSA-N

Sources

  • British National Formulary
  • K4DD Project
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1201247

Molecule Features

CHEMBL1201247 compound icon
Drug Type:Oligopeptide Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Gonadotropin-releasing hormone receptor agonist Gonadotropin-releasing hormone receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Breast Neoplasms, MaleD018567EFO:0006861male breast carcinoma1ClinicalTrials
Hodgkin DiseaseD006689EFO:0000183Hodgkins lymphoma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials
ClinicalTrials
LeiomyomaD007889EFO:0000731uterine fibroid3ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma3ClinicalTrials
ClinicalTrials
MenopauseD008593EFO:0003922menopause3ClinicalTrials
EndometriosisD004715EFO:0001065endometriosis3ClinicalTrials
SarcopeniaD055948EFO:1000653sarcopenia3ClinicalTrials
InfertilityD007246EFO:0000545infertility3ClinicalTrials
ClinicalTrials
Metabolic SyndromeD024821EFO:0000195metabolic syndrome2ClinicalTrials
ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma3ClinicalTrials
ClinicalTrials

Clinical Data

ClinicalTrials.gov GOSERELIN
The Cochrane Collaboration GOSERELIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
1269.4 1268.6414 - - - -


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
- - - - - -


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- - - - - - -0

Structural Alerts

There are no structural alerts for CHEMBL1201247

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 - ENDOCRINE THERAPY
L02A - HORMONES AND RELATED AGENTS
L02AE - Gonadotropin releasing hormone analogues
L02AE03 - goserelin

ChemSpider ChemSpider:BLCLNMBMMGCOAS-URPVMXJPSA-N
DailyMed goserelin acetate
Wikipedia Goserelin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1201247



ACToR 65807-02-5
ChEBI 5523
DrugBank DB00014
DrugCentral 1327
EPA CompTox Dashboard DTXSID7048297
FDA SRS 0F65R8P09N
Guide to Pharmacology 3879
Human Metabolome Database HMDB0014259
IBM Patent System D1B2BEA54E4A541DF090E6FC6E341B7D
LINCS LSM-46023
MolPort MolPort-006-823-831
Nikkaji J34.701I
PubChem 5311128
PubChem: Drugs of the Future 12012688
PubChem: Thomson Pharma 14841899
SureChEMBL SCHEMBL19712239 SCHEMBL20459194 SCHEMBL8643

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/BLCLNMBMMGCOAS-URPVMXJPSA-N spacer
spacer